Immune modulation of i.v. immunoglobulin in women with reproductive failure

Reproductive Medicine and Biology - Tập 17 Số 2 - Trang 115-124 - 2018
Ae Ra Han1,2, Sung Ki Lee3
1Department of Obstetrics and Gynecology, Eulji University College of Medicine, Daejeon, South Korea
2Department of Obstetrics and Gynecology, Gangseo Mizmedi Hospital, Seoul, South Korea
3Department of Obstetrics and Gynecology, Konyang University College of Medicine, Daejeon, South Korea

Tóm tắt

AbstractBackgroundThe mechanism of maternal immune tolerance of the semi‐allogenic fetus has been explored extensively. The immune reaction to defend from invasion by pathogenic microorganisms should be maintained during pregnancy. An imbalance between the immune tolerance to the fetus and immune activation to the pathogenic organisms is associated with poor pregnancy outcomes. This emphasizes that the immune mechanism of successful reproduction is not just immune suppression, but adequate immune modulation.MethodsIn this review, the action of i.v. immunoglobulin G (IVIg) on the immune system and its efficacy in reproductive failure (RF) was summarized. Also suggested is the indication of IVIg therapy for women with RF.Main findings (Results)Based on the mechanism of the immune regulation of IVIg and following confirmation of the immune modulation effects of it in various aberrant immune parameters in patients with RF, it is obvious that IVIg is effective in recurrent pregnancy losses and repeated implantation failures with immunologic disturbances.ConclusionThe authors recommend IVIg therapy in patients with RF with aberrant cellular immunologic parameters, including a high natural killer cell proportion and its cytotoxicity or elevated T helper 1 to T helper 2 ratio, based on each clinic's cut‐off values. Further clinical studies about the safety of IVIg in the fetus and its efficacy in other immunologic abnormalities of RF are needed.

Từ khóa


Tài liệu tham khảo

10.1016/S0015-0282(16)58144-8

Preterm birth.World Health Organization Web site.http://www.who.int/mediacentre/factsheets/fs363/en/Published. Updated. Accessed November 2016

10.1111/j.1600-0897.2010.00852.x

10.1016/j.transci.2016.12.017

10.1016/S0140-6736(81)92400-4

10.1056/NEJMra993360

10.1038/nri3401

Abbas AK, 2015, Cellular and Molecular Immunology

10.1007/978-1-4614-3461-0_10

10.1182/blood-2002-05-1447

10.1073/pnas.0900016106

10.1016/j.clim.2011.06.009

10.1038/ni.1778

10.1038/nature10134

10.1186/ar2892

10.1172/JCI200522753

10.1038/nm1416

10.1182/blood-2009-06-225417

10.1172/JCI24772

10.1073/pnas.0402183101

10.1016/j.clim.2009.09.006

10.1126/science.1129594

10.1182/blood-2007-03-077057

Prasad NK, 1998, Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway, J Immunol, 161, 3781, 10.4049/jimmunol.161.7.3781

10.1073/pnas.0807319106

10.1016/S1074-7613(03)00080-3

Mouzaki A, 2002, Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis, Blood, 100, 1774, 10.1182/blood.V100.5.1774.h81702001774_1774_1779

10.1097/01.tp.0000226073.20185.b1

10.1006/clin.1994.1186

Hurez V, 1994, Anti‐CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg), Ther Immunol, 1, 269

10.1073/pnas.89.8.3325

10.1182/blood-2007-03-079947

10.1016/j.imlet.2012.12.011

10.4049/jimmunol.179.8.5571

10.1002/eji.200636480

10.1182/blood-2008-02-138073

10.1007/s10875-012-9752-6

10.1016/j.jaci.2010.12.1102

10.1073/pnas.93.11.5512

10.1172/JCI24394

10.1111/j.1600-0897.2012.01178.x

10.1038/nm1452

10.1196/annals.1434.013

10.1111/j.1479-828X.1999.tb03139.x

10.1016/S0143-4004(05)80184-5

10.1093/humrep/16.12.2593

10.1111/j.1471-0528.2008.01978.x

10.1111/j.1447-0756.2009.01079.x

10.1111/j.1600-0897.2009.00714.x

10.1111/j.1600-0897.1996.tb00495.x

10.1056/NEJM198802253180816

Smith CI, 1985, Intravenous immunoglobulin in pregnancy, Obstet Gynecol, 66, 39S

Ford HB, 2009, Recurrent pregnancy loss: etiology, diagnosis, and therapy, Rev Obstet Gynecol, 2, 76

10.1111/j.1423-0410.1989.tb02018.x

10.1111/j.1600-0897.1994.tb01127.x

10.1093/oxfordjournals.humrep.a137724

10.1007/BF02576257

10.1111/j.1600-0897.1994.tb01126.x

Wong LF, 2014, Immunotherapy for recurrent miscarriage, Cochrane Database Syst Rev, 10, CD000112

10.1097/00001703-199304000-00014

10.1111/j.1600-0897.1992.tb00738.x

10.1016/0002-9378(92)91785-9

10.1111/aji.12208

10.1111/j.1600-0897.1995.tb00924.x

10.1001/jama.1995.03520480053039

10.1016/S0140-6736(95)92539-2

10.1111/j.1600-0897.1996.tb00496.x

10.1111/j.1600-0897.1999.tb00102.x

10.1093/humrep/der301

10.1007/s10815-005-9013-1

10.1111/j.1600-0897.2006.00368.x

10.1111/j.1600-0897.2007.00529.x

10.1111/aji.12442

10.1111/aji.12217

10.1016/S0015-0282(99)00495-1

10.1111/j.1600-0897.2011.01018.x

10.1111/j.1600-0897.2012.01135.x

10.1111/j.1600-0897.2005.00255.x

10.1016/j.rbmo.2012.07.004

10.1093/humrep/dem383

10.1016/j.fertnstert.2009.08.062

10.1093/molehr/gal032

10.1093/humrep/deg156

10.1016/j.fertnstert.2014.08.029

10.1182/blood-2007-12-129627

10.1016/S0140-6736(88)92859-0

10.1016/0002-9378(88)90411-5

10.7326/0003-4819-109-12-993

10.1016/0002-9378(89)90681-9

Harris EN, 1998, Utilization of intravenous immunoglobulin therapy to treat recurrent pregnancy loss in the antiphospholipid syndrome: a review, Scand J Rheumatol, 107, 97, 10.1080/03009742.1998.11720777

10.1093/humrep/17.3.809

10.1111/j.8755-8920.2001.450309.x

10.1002/art.10957

10.5653/cerm.2017.44.1.1

10.3109/09513590.2013.864271

10.1111/j.1600-0897.1996.tb00497.x

10.1034/j.1600-0897.2003.00095.x

10.1093/humrep/dep349

10.1111/aji.12137

10.1056/NEJM198602273140907

10.1016/j.jaci.2011.06.047

Zhang R, 2000, Reemergence of sucrose nephropathy: acute renal failure caused by high‐dose intravenous immune globulin therapy, South Med J, 93, 901

10.1001/archneur.1993.00540020013009

Kinney J, 1991, Efficacy and pharmacokinetics of intravenous immune globulin administration to high‐risk neonates, Am J Dis Child, 145, 1233

Ohlsson A, 2010, Intravenous immunoglobulin for suspected or subsequently proven infection in neonates, Cochrane Database Syst Rev, 3, CD001239

10.1016/j.ajog.2004.02.002

Thông tin
Thông tin xuất bản

Reproductive Medicine and Biology

Tập 17 Số 2

115-124

Thông tin tác giả